ERBB2 and gastric cancer: Based on these studies, patients with human epidermal growth factor receptor-2 (HER-2)-negative advanced gastric cancers with high programmed death ligand-1 (PD-L1) expression should be treated with platinum-fluoropyrimidine doublet combined with PD-1 inhibitor.